Substance Use Disorders Clinical Trial
Official title:
Maximizing Effectiveness of Integrated Treatment Approaches
The purpose of the study is to evaluate methods to help people in substance abuse treatment receive better psychiatric care. Patients enrolled in the study will be offered three months of standard psychiatric treatment, which consists of weekly individual counseling and group counseling, as well as regular appointments with a psychiatrist. Patients will be randomly assigned to standard psychiatric care or standard psychiatric care plus voucher incentives. These incentives can be earned by successfully attending all scheduled psychiatric appointments each week. The investigators expect that patients in the voucher condition will attend more psychiatric sessions, which will lead to greater reductions in psychiatric distress.
Male and female opioid-dependent patients at Addiction Treatment Services with any current psychiatric disorder (N = 100) will be randomly assigned to one of two psychiatric service conditions: 1) reinforced on-site integrated care (ROIC), with voucher incentives contingent on attending weekly psychiatric sessions; or 2) standard on-site integrated care (SOIC). Participants in both conditions will receive access to the same schedule and range of psychiatric and substance abuse treatment services. Participants will be assessed for 3-months post-randomization to determine rates of service utilization and adherence to psychiatric care, changes in scope and severity of psychiatric and psychosocial problems, and rates of drug use and treatment retention. Positive findings would have considerable heuristic and health care policy and practice implications. The entire study, including dissemination of the major findings at a national meeting and submission of the first manuscript, is designed to be completed within 2-years. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05660434 -
Using Aromatherapy in Substance Use Disorder
|
N/A | |
| Active, not recruiting |
NCT05338268 -
Substance Use and Loneliness
|
N/A | |
| Completed |
NCT04098614 -
Barriers to Substance Use Disorder Recovery
|
N/A | |
| Completed |
NCT03954184 -
E-health Implementation (Iowa)
|
N/A | |
| Completed |
NCT03590106 -
Cardiac Surgery Peer Recovery Support Program
|
N/A | |
| Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
| Recruiting |
NCT06273228 -
Parenting Young Children in Pediatrics
|
N/A | |
| Recruiting |
NCT05327504 -
Written Exposure Therapy for Veterans With SUD and PTSD
|
N/A | |
| Terminated |
NCT03517111 -
The Impact of a Parenting Intervention on Latino Youth Health Behaviors
|
N/A | |
| Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
| Completed |
NCT04401215 -
Technologically-Augmented Referrals to Mitigate Addiction Consequences
|
N/A | |
| Not yet recruiting |
NCT06187701 -
Co-Active Therapeutic Theatre (Co-ATT) for Dual-Diagnosis Patients
|
N/A | |
| Not yet recruiting |
NCT06163651 -
Evaluating a One-Year Version of the Parent-Child Assistance Program
|
N/A | |
| Recruiting |
NCT04296604 -
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
|
N/A | |
| Active, not recruiting |
NCT02382042 -
Intensive Referral Intervention to Improve Substance Use Disorder Treatment Outcomes Among Rural and Highly Rural Veterans
|
N/A | |
| Completed |
NCT01237366 -
Study Targeting Affect Regulation
|
Phase 1/Phase 2 | |
| Terminated |
NCT01356667 -
Drum-Assisted Therapy for Native Americans
|
N/A | |
| Completed |
NCT00708890 -
Twelve Step Based Self-help Groups for Substance Related Disorders
|
N/A | |
| Active, not recruiting |
NCT04048850 -
Zepatier in Patients With Substance Use
|
||
| Recruiting |
NCT05976646 -
Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion
|
Phase 1/Phase 2 |